Literature DB >> 16499280

HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver.

Mark D Erion1, David A Bullough, Chin-Chung Lin, Zhi Hong.   

Abstract

HepDirect prodrugs represent a novel class of cytochrome P450-activated prodrugs capable of targeting certain drugs to the liver. In this review, the HepDirect prodrug concept and its use for the delivery of nucleotides to the liver for the treatment of viral hepatitis is summarized. Preclinical and clinical data for the most advanced HepDirect prodrug, pradefovir, highlight the liver-targeting capability of these prodrugs, and the potential benefit of liver targeting on drug efficacy, safety and viral resistance.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16499280

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  7 in total

Review 1.  Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Authors:  Drew R Bobeck; Raymond F Schinazi; Steven J Coats
Journal:  Antivir Ther       Date:  2010

2.  Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees.

Authors:  Steven S Carroll; Kenneth Koeplinger; Marissa Vavrek; Nanyan Rena Zhang; Laurence Handt; Malcolm MacCoss; David B Olsen; K Raja Reddy; Zhili Sun; Paul D van Poelje; James M Fujitaki; Serge H Boyer; David L Linemeyer; Scott J Hecker; Mark D Erion
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

Review 3.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 4.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

5.  Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.

Authors:  Kristiina M Huttunen; Niina Mähönen; Jukka Leppänen; Jouko Vepsäläinen; Risto O Juvonen; Hannu Raunio; Hanna Kumpulainen; Tomi Järvinen; Jarkko Rautio
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

Review 6.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

7.  In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.

Authors:  Inemesit A Udofia; Kofoworola O Gbayo; Oluwakemi A Oloba-Whenu; Taofeek B Ogunbayo; Chukwuemeka Isanbor
Journal:  Netw Model Anal Health Inform Bioinform       Date:  2021-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.